Tuberculosis in the age of biologic therapy

Journal of the American Academy of Dermatology

Volumn 59, Issue 3, 2008, Pages 363-380

  Hernandez, Claudia ^a   Cetner, Aaron S ^a   Jordan, J Edward ^b   Puangsuvan, Somchin N ^a   Robinson, June K ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Provena Health eICU   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AMPRENAVIR; BCG VACCINE; CORTICOSTEROID DERIVATIVE; EFALIZUMAB; EFAVIRENZ; ETANERCEPT; ETHAMBUTOL; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; INFLIXIMAB; ISONIAZID; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ASPERGILLOSIS; BCG VACCINATION; BIOLOGICAL THERAPY; BURSITIS; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CRYPTOCOCCOSIS; CYTOKINE RELEASE; DISEASE TRANSMISSION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; GEOGRAPHIC DISTRIBUTION; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT PERIOD; LISTERIOSIS; MEDICAL SPECIALIST; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SCREENING TEST; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS PNEUMONIA;

ANTITUBERCULAR AGENTS; BIOLOGICAL THERAPY; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE II; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; PSORIASIS; T-LYMPHOCYTES; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49049118261     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.05.033     Document Type: Review

References (110)

1. World Health Organization. Global tuberculosis control. Surveillance, planning, financing. WHO Report 2005 (2005), World Health Organization, Geneva, Switzerland pp. 1-247
2. Starke J., Jacobs R., and Jereb J. Resurgence of tuberculosis in children. J Pediatr 120 (1992) 839-855
3. Kaufmann S.H. New issues in tuberculosis. Ann Rheum Dis 63 suppl 2 (2004) ii50-ii56
4. Boshoff H.I., and Barry III C.E. Tuberculosis-metabolism and respiration in the absence of growth. Nat Rev Microbiol 3 (2005) 70-80
5. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2005 (2006), US Department of Health and Human Services, Atlanta, GA
6. Schneider E., Moore M., and Castro K.G. Epidermiology of tuberculosis in the United States. Clin Chest Med 26 (2005) 183-195
7. Brudney K., and Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculsosis control programs. Am Rev Respir Dis 144 (1991) 745-749
8. McKenna M.T., McCray E., and Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med 332 (1995) 1071-1076
9. Centers for Disease Control and Prevention Web site. National Center for HIV/AIDS, viral hepatitis, STD, and TB prevention, Division of Tuberculosis Elimination. Surveillance Reports: Reported Tuberculosis in the United States, 2005. Available from: http://www.cdc.gov/tb/surv/surv2005/PDF/table28.pdf. Accessed June 13, 2008.
10. Lobato M.N., and Cegielski J.P. Preventing and controlling tuberculosis along the US-Mexico border. MMWR Morb Mortal Wkly Rep 50 (2001) 1-28
11. Centers for Disease Control and Prevention Web site. Division of Global Migration and Quarantine. Technical instruction for panel physicians. Available from: www.cdc.gov/ncidod/dq/panel.htm. Accessed June 13, 2008.
12. Talbot E.A., Moore M., McCray E., and Binkin N.J. Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA 284 (2000) 2894-2900
13. Beck-Sague C., Dooley S.W., Hutton M.D., Otten J., Breeden A., Crawford J.T., et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. JAMA 268 (1992) 1280-1286
14. Maher D., and Ravigilione M. Global epidemiology of tuberculosis. Clin Chest Med 26 (2005) 167-182
15. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Resp Crit Care Med 161 (2000) 1376-1395
16. Murray J.F. Bill Dock and the location of pulmonary tuberculosis: how bed rest might have helped consumption. Am J Respir Crit Care Med 168 (2003) 1029-1033
17. Jindani A., Aber E., Edwards E., and Mitchison D. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121 (1980) 939-949
18. Bozzi C.J., Burwen D.R., Dooley S.W., Simone P.M., Beck-Sague C., Bolyard E.A., et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR Morb Mortal Wkly Rep 43 (1994) 1-132
19. Horsburgh J. Tuberculosis without tubercles. Tuber Lung Dis 77 (1996) 197-198
20. Edwards D., and Kirkpatrick C.H. The immunology of mycobacterial diseases. Am Rev Respir Dis 134 (1986) 1062-1071
21. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161 4 pt 2 (2000) S221-S247
22. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., and Dye C. Tuberculosis. Lancet 362 (2003) 887-899
23. Kaufmann S.H. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 26 (2005) 660-667
24. Hartmann P., and Plum G. Immunological defense mechanisms in tuberculosis and MAC-infection. Diagn Microbio Infect Dis 34 (1999) 147-152
25. Vos A.M., Meima A., Verver S., Looman C.W.N., Bos V., Borgdorff M.W., et al. High incidence of pulmonary tuberculosis persists a decade after immigration, the Netherlands. Emerg Infect Dis 10 (2004) 736-739
26. Zuber P.L., McKenna M.T., Binkin N.J., Onorato I.M., and Castro K.G. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 278 (1997) 304-307
27. Dannenberg Jr. A.M., and Tomashefski Jr. J.F. Pathogenesis of pulmonary tuberculosis. In: Fishman A.P., Elias J.A., Fishman J.A., Grippi M.A., Kaiser L.R., and Senior R.M. (Eds). Fishman's pulmonary diseases and disorders (1998), McGraw Hill, New York 2447-2471
28. Menon M.P.S. A new look at the immunology of tuberculosis. Indian J Tuberc 44 (1997) 3-8
29. Reggiardo Z., and Middlebrook G. Failure of passive serum transfer of immunity against aerogenic tuberculosis in guinea pigs. Proc Soc Exp Biol Med 145 (1974) 173-175
30. Toussirot E., Streit G., and Wendling D. Infectious complications with anti-TNFα therapy in rheumatic diseases: a review. Recent Patents Inflamm Allergy Drug Discovery 1 (2007) 39-47
31. Chesnutt M.S., and Prendergast T.J. Pulmonary tuberculosis. In: McPhee S.J., Papadakis M.A., and Tierney L.M. (Eds). Current medical diagnosis and treatment 2007 (2007), McGraw-Hill, New York 260-268
32. Jones B., Young S., Antoniskis D., Davidson F., Kramer F., and Barnes P. Relationship of the manifestations of tuberculosis to CD4 counts in patients with HIV infection. Am Rev Respir Dis 148 (1993) 1292-1297
33. Small P.M., Schecter G.F., Goodman P.C., Sande M.A., Chaison R.E., and Hopewell P.C. Treatment of tuberculosis in patient with advanced HIV infection. N Engl J Med 324 (1991) 289-294
34. Rossman M.D., and Oner-Eyuboglu A.F. Clinical presentation and treatment of tuberculosis. In: Fishman A.P., Elias J.A., Fishman J.A., Grippi M.A., Kaiser L.R., and Senior R.M. (Eds). Fishman's pulmonary diseases and disorders (1998), McGraw Hill, New York 2483-2501
35. Yorken H., Massy S.G., Fallat R., Kaplan L., and Kleeman C.R. Antidiuretic principle in tuberculosis lung tissue of a patient with pulmonary tuberculosis and hyponatremia. Ann Intern Med 72 (1970) 383-387
36. Geng E., Kreisworth B., Burzynski J., and Schluger N.W. Clinical and radiographic correlates of primary and reactivation tuberculosis, a molecular epidemiology study. JAMA 293 (2005) 2740-2745
37. Jones B.E., Ryu R., Yang Z., Cave M.D., Pogoda J.M., Otaya M., et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med 156 (1997) 1270-1273
38. Beutler B., and Cermai A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320 (1986) 584-588
39. Papadakis K.A., and Targan S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119 (2000) 1148-1157
40. Ettehadi P., Greaves M.W., Wallach D., Aderka D., and Camp R.D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96 (1994) 146-151
41. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
42. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet 3 (2003) 148-155
43. Mackay F., Loetscher H., Stueber D., Gehr G., and Lesslauer W. Tumor necrosis factor alpha (TNF alpha) induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type (TNF-R55). J Exp Med 177 (1993) 1277-1286
44. Mutlu G.M., Mutlu E.A., Bellmeyer A., and Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-α antibody therapy. Am J Med 119 (2006) 639-646
45. Flynn J.L., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 19 (2001) 93-129
46. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., et al. Effects of tumor necrosis factor-α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immunol 69 (2001) 1847-1855
47. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clin Infect Dis 41 suppl 3 (2005) S199-S203
48. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
49. Botha T., and Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 171 (2003) 3110-3118
50. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., and Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002) 4620-4627
51. Turner J., Frank A.A., Brooks J.V., Marietta P.M., and Orme I.M. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 102 (2001) 248-253
52. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162 (1999) 3504-3511
53. Keane J., Gershon S.K., and Braun M.M. Tuberculosis and treatment with infliximab. N Engl J Med 346 (2002) 623-626
54. Keane J., Gershon S.K., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 345 (2001) 1098-1104
55. Iliopoulos A., Psathakis K., Aslandis S., Skagias L., and Sfikakis P.P. Tuberculosis and granuloma formation in patients recieving anti-TNF therapy. Int J Tuberc Lung Dis 10 (2006) 588-590
56. Lügering A., Schmidt M., Lügering N., Pauels H.G., Domschke W., and Kucharzik T. Infliximab induced apoptosis in monocytes from patients with chronic active Crohn's disease by using a capase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
57. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 354 (1999) 1932-1939
58. Wolfe F., Michaud K., Anderson J., and Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rhuem 50 (2005) 372-379
59. Remicade (package insert) (April 2007), Centocor, Inc, Malvern, PA. http://www.remicade.com/pdf/HCP_PPI.pdf Accessed June 13, 2008
60. Long R., and Gardam M. Tumor necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. Can Med Assoc J 168 (2003) 1153-1156
61. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Coster L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
62. Mohan A.K., Coté T.R., Block J.A., Manadan A.M., Siegel J.N., and Braun M.M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39 (2004) 295-299
63. Hamdi H., Mariette X., Godot V., Weldingh K., Hamid A.M., Prejean M.V., et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor anatagonists. Arthritis Res Ther 8 (2006) R114
64. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US post-marketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 889-894
65. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44 (2005) 714-720
66. Humira (package insert) (December 2002), Abbott Laboratories, Chicago, IL. http://www.fda.gov/cder/foi/label/2002/adalabb123102LB.htm Accessed June 13, 2008
67. Perez J, Kupper H, Okun M. Screening outcomes for latent TB in worldwide adalimumab clinical trials. Presented at the 65th Annual Meeting of the American Academy of Dermatology, Washington, DC, February 2-7, 2007.
68. Chin R. Raptiva (efalizumab) safety. Available from: www.fda.gov/ohrms/dockets/ac/03/slides/3983S1_02_E-Genentech-Safety.ppt. Accessed June 13, 2008.
69. Raptiva (package insert) (2005), Genentech Inc, San Francisco, CA. http://www.gene.com/gene/common/inc/pi/raptiva.jsp Accessed June 13, 2008
70. Amevive (package insert) (October 2006), Astellas Pharma US, Inc, Deerfield, IL. http://www.astellas.us/docs/amevive.pdf Accessed June 13, 2008
71. van Ingen J., Boeree M., Janssen M., Ullmann E., de Lange W., de Haas P., et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 3 (2007) 414-419
72. Yim K., Nazeer S.H., Kiska D., Rose F.B., Brown D., and Cynamon M.H. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis 36 (2004) 150-154
73. Boulman N., Rozenbaum M., Slobodin G., and Rosner I. Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 24 (2006) 723
74. Phillips K., Husni M.E., Karlson E.W., and Coblyn J.S. Experience with etanercept in an academic medical centre: are infection rates increased?. Arthritis Rheum 47 (2002) 17-21
75. Mufti A.H., Toye B.W., Mckendry R.R.J., and Angel J.B. Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use. Diagn Microbiol Infect Dis 53 (2005) 233-238
76. Prasertsuntarasai T., and Bello E.F. Mycobacterium avium complex olecranon bursitis in a patient treated with alefacept. Mayo Clin Proc 8 (2005) 1530-1533
77. Ayub A., Yale S.H., and Reed K.D. Testing for latent tuberculosis. Clin Med Res 2 (2004) 191-194
78. Tubersol (package insert). Canada: Connaught; 1994. Available from: http://www.drugs.com/mmx/tuberculin-purified-protein-derivative.html. Accessed June 13, 2008.
79. Friedman L.N., Nash E.R., Bryant J., Henry S., Shi J., D'Amato J., et al. High rate of negative results of Tuberculin and QuantiFERON tests among individuals with a history of positive skin test results. Infect Control Hosp Epidemiol 27 (2006) 436-441
80. Centers for Disease Control and Prevention. Anergy skin testing and preventative therapy for HIV-infected persons: revised recommendations. MMWR Morb Mortal Wkly Rep 46 (1997) 1-10
81. Harboe M. Antigens of PPD, old tuberculin, and autoclaved Mycobacterium bovis BCG studied by crossed immunoelectrophoresis. Am Rev Respir Dis 124 (1981) 80-87
82. Menzies R., and Vissandjee B. Effect of bacilli Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis 145 (1992) 621-625
83. Huebner R.E., Schien M.F., and Bass Jr. J.B. The tuberculin skin test. Clin Infect Dis 17 (1993) 968-975
84. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 49 (2000) 1-54
85. Pai M., Kalantri S., and Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 6 (2006) 413-422
86. Centers for Disease Control and Prevention Web site. Division of Tuberculosis Elimination. Fact sheets: Quantiferon-TB gold test. Available from: www.cdc.gov/tb/pubs/tbfactsheets/QFT.htm. Accessed June 13, 2008.
87. Nahid P., Pai M., and Hopewell P.C. Advances in the diagnosis and treatment of tuberculosis. Am Thorac Soc 3 (2006) 103-110
88. Mazurek G.H., Jereb J., LoBue P., Iademarco M.F., Metchock B., and Vernon A. Guidelines for using QuantiFeron-TB-GOLD test for detecting Mycobacterium tuberculosis infection, United States. MMWR Morb Mortal Wkly Rep 54 (2005) 49-55
89. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infection tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 1-55
90. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 159 (1999) 15-21
91. Kang Y.A., Lee H.W., Yoon H.I., Cho B., Han S.K., Shim Y.S., et al. Discrepancy between the tuberculin skin test and the whole blood-blood interferon γ assay for the diagnosis of latent tuberculosis in an intermediate tuberculosis-burden country. JAMA 293 (2005) 2756-2761
92. Pai M., Gokhale K., Joshi R., Dogra S., Kalantri S., Mendiratta D.K., et al. Mycobacterium tuberculosis infection in health care workers in rural India: a comparison of whole blood interferon-γ assay with tuberculin skin testing. JAMA 293 (2005) 2746-2755
93. Mahomed H., Hughes E.J., Hawkridge T., Minnies D., Simon E., Little F., et al. Comparison of Mantoux skin test with three generations of a whole blood IFN-γ assay for tuberculosis infection. Int J Tuber Lung Dis 10 (2006) 310-316
94. Chapman A.L., Munkanta M., Wilkinsin K.A., Pathan A.A., Ewer K., Ayles H., et al. Rapid detection of active and latent tuberculosis infection in HIV-postive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16 (2002) 2285-2293
95. Liebeschuetz S., Bamber S., Ewer K., Deeks J., Pathan A., and Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell based assay: a prospective cohort study. Lancet 364 (2004) 2196-2203
96. Lalvani A., Pathan A.A., Durkan H., Wilkonson K., Whelan A., Deeks J.J., et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357 (2001) 2017-2021
97. Pai M., Joshi R., Dogra S., Mendiratta D.K., Narang P., Kalantri S., et al. Serial testing of health care workers for tuberculosis using interferon γ assay. Am J Resp Crit Care Med 174 (2006) 349-355
98. Whalen C.C. Diagnosis of latent tuberculosis infection: measure for measure. JAMA 293 (2005) 2785-2787
99. Hatemi G., Melikoglu M., Fesko I., Masatlioglu S., Tascilar K., and Yazici H. Infliximab does not suppress the tuberculin skin test. J Rheum 34 (2007) 474-480
100. Brodie D., and Schluger N.W. The diagnosis of tuberculosis. Clin Chest Med 26 (2005) 247-271
101. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations, 1998. Thorax 53 (1998) 536-548
102. Ormerod L.P. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 78 (1998) 169-171
103. Van der Klooster J.M., Bosman R.J., Oudemans-van Straaten H.M., van der Spoel J.I., Wester J.P.J., and Zandstra D.F. Disseminated tuberculosis, pulmonary aspergillosis, and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29 (2003) 2327-2329
104. Hernandez-Cruz B., Ponce-de-Léon-Rosales S., Sifuentes-Osornio J., Ponce-de-Léon Garduño A., and Diaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases: a case-control study. Clin Exp Rheumatol 17 (1999) 81-87
105. Sichletidis L., Settas L., Spyratos D., Chloros D., and Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10 (2006) 1127-1132
106. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 52 (2003) 1-77
107. Ormerod L.P. Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF treatment. Cytokine 28 (2004) 179-181
108. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., and Montero M.D. BIOBADASER group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 48 (2003) 2122-2127
109. RATIO observatory Web site. Available from: www.observatoire-ratio.org. Accessed June 13, 2008.
110. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. Morb Mortal Wkly Rep Recomm Rep 44 (1995) 18-34